XLR-11 (5"-fluoro-UR-144) is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not listed in the patent or scientific literature alongside these other similar compounds,[1][2] and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196.
Detection [edit]
 |
This section is empty. You can help by adding to it. (March 2013) |
Recreational use [edit]
XLR-11 was instead first identified by laboratories in 2012 as an ingredient in synthetic cannabis smoking blends, and appears to be a novel compound invented by "research chemical" suppliers specifically for grey-market recreational use. It was banned in New Zealand by being added to the temporary class drug schedule, effective from 13 July 2012.[3] It has also been banned in Florida as of 11 December 2012.[4]
Toxicity [edit]
XLR-11 has been linked to acute kidney injury in some users, along with AM-2201.[5][6]
See also [edit]
References [edit]
- ^ WO application 2006069196, Pace JM, Tietje K, Dart MJ, Meyer MD, "3-Cycloalkylcarbonyl indoles as cannabinoid receptor ligands", published 2006-06-29, assigned to Abbott Laboratories
- ^ Frost JM, et al. (January 2010). "Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity". J. Med. Chem. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
- ^ Temporary Class Drug Notice, 5 July 2012. NZ Department of Internal Affairs.
- ^ Florida Attorney General Pam Bondi Outlaws Additional Synthetic Drugs
- ^ Bhanushali, G. K.; Jain, G.; Fatima, H.; Leisch, L. J.; Thornley-Brown, D. (2012). "AKI Associated with Synthetic Cannabinoids: A Case Series". Clinical Journal of the American Society of Nephrology. doi:10.2215/CJN.05690612. PMID 23243266. edit
- ^ "Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012". US Centre for Disease Control. 15 Feb 2013. Retrieved 2013-02-15.
|
|
|
| Phytocannabinoids |
|
|
Cannabinoid
metabolites |
|
|
Endogenous
cannabinoids |
|
|
Synthetic
cannabinoid
receptor
agonists |
Classical
cannabinoids
(Dibenzopyrans) |
|
|
Nonclassical
cannabinoids |
|
|
| Benzoylindoles |
|
|
| Naphthoylindoles |
|
|
| Naphthylmethylindoles |
|
|
| Phenylacetylindoles |
|
|
| Naphthoylpyrroles |
|
|
| Eicosanoids |
|
|
| Others |
|
|
|
Allosteric
modulators of
cannabinoid
receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid
receptor
antagonists and
inverse agonists |
|
|
